Table 2.

Summary of various clinical studies.

S. No.	Study design	Dosage of BME	Intervention	Clinical outcomes	References
1.	46 healthy participants (males = 11; females = 35). Aged between 18 and 60 years.	300 mg/day	12 weeks	Significant improvement in speed of visual information processing and learning rate. Concentrations were noticed with a reduction in state anxiety.	(103)
2.	107 healthy volunteers. Aged between 18 and 60 years.	300 mg/day	90 days	Increases accuracy and memory consolidation	(104)
3.	76 participants. Aged between 40 and 65 years.	300 mg for persons under 90 kg, and 450 mg for persons over 90 kg	90 days	Significant reduction in the rate at which freshly acquired information is forgotten	(105)
4.	98 healthy adults. Aged over 55 years.	300 mg/day	12 weeks	Improvement in-memory performance and retention.	(106)
5.	60 healthy elderlies (males = 23; females = 37).	300 mg/day	12 weeks	Improvement in the working memory, attention, and cognitive processing.	(107)
6.	17 healthy volunteers.	320 mg BM and 640 mg of BM	-	Reduced stress and improved mood.	(108)
7.	100 volunteers (male children and adolescents).	160 mg/day 320 mg/day	16 weeks	Increased cognitive function.	(109)
8.	60 Medical Students.	150 mg (b.i.d.)	6 weeks	Cognitive enhancement.	(110)
9.	12 patients. Aged 18 and more.	250 mg (b.i.d.)	3 months	Effective for treatment of dementia.	(111)
10.	19 patients.	300 mg bid	4 weeks	Effective for managing anhedonia.	(112)